Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for CSL.AX and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for CSL.AX and 80,000+ other tickers.
See exactly how CSL.AX's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for CSL.AX and 80,000+ other tickers.
CSL Limited operates as a global biopharmaceutical company, engaged in the research, development, manufacturing, marketing, and distribution of diverse pharmaceutical and allied products. Its extensive international footprint includes key markets such as Australia, the United States, Germany, the United Kingdom, Switzerland, and China. The company is structured into two principal operating segments: CSL Behring and CSL Seqirus. CSL Behring focuses on plasma-derived therapies, encompassing both plasma products and recombinant treatments. This segment also conducts significant research into…
CSL Limited (ASX: CSL - Get Free Report) insider Robert Cuthbertson purchased 183 shares of the business's stock in a transaction on Tuesday, February 17th. The shares were bought at an average cost of A$151.56 per share, for a total transaction of A$27,734.93. CSL Stock Performance The company has a market cap of $77.43 billion, a
CSL Limited (ASX: CSL - Get Free Report) insider Carolyn Hewson acquired 244 shares of the firm's stock in a transaction on Tuesday, February 17th. The stock was purchased at an average cost of A$151.56 per share, with a total value of A$36,979.91. CSL Stock Performance The stock has a market capitalization of $77.43 billion, a